Did you know that a survey with 252 dermatologists and dermatology office managers found that 60% of dermatologists have to interrupt their patient visits to respond to prior authorization (PA) requests? That’s not all, 17% of PAs forced patients to use less effective treatment options, while 12% of PAs resulted in patients either delaying or abandoning the treatment.
These numbers are enough to understand how prior authorization challenges in dermatology impact timely care delivery. This guide discusses the topic in detail, from explaining why pre-authorization takes longer in dermatology, to what’s new in dermatology PA guidelines, and everything in between.
Thus, if you are a dermatologist struggling with PAs, continue reading!
Why Prior Authorization Takes Longer in Dermatology Practices?
Prior authorization challenges in dermatology are significantly higher than in any other specialty. Besides, it generally takes longer to secure approval from the insurance carrier. But what contributes to these delays?
Let’s review the key factors:
Cosmetic vs. Medical Classification
Dermatologists often struggle to prove the medical necessity of the procedures. The reason? Payers categorize treatments for conditions, such as scarring, severe acne, or autoimmune-related skin issues, as cosmetic.
High-Cost Specialty Medications
Advanced biologic therapies, such as Skyrizi, Humira, and Dupixent, are on the rise. However, since these therapies are expensive, payer scrutiny has increased towards dermatology practices.
That is, insurance carriers demand dermatology practices to provide proof of medical necessity. This prior authorization requirement requires exhaustive documentation, often delaying the approval.
Mandatory Step Therapy
Oftentimes, insurance payers enforce fail-first protocols. This means patients must first try and fail multiple lower-cost oral or topical treatments before going for biologics.
The repercussions? Dermatologists must document years of pre-treatment history. This eats up staff time and stalls immediate care delivery due to prior authorization delays.
Documentation Hurdles
Outdated or incomplete documentation poses another authorization challenge in dermatology. That is, it can delay approvals since the insurance carrier specifically looks for:
- Diagnosis severity scores.
- Measured responses to previous therapies.
- Specific lab results for safety monitoring.
Payer-Specific Policies
Note that prior authorization requirements may vary across payers. Thus, dermatology clinics may spend several hours daily navigating these inconsistent rules. The outcome? It slows down the PA process.
What’s New in Dermatology Prior Approval Guidelines?
The following are prior authorization approval guidelines that dermatology practices should know about:
Federal Decision Timelines
The Centers for Medicare & Medicaid Services (CMS) implemented the Interoperability and Prior Authorization Final Rule (CMS-0057-F) back in 2024.
Do you want to know its impact? It strictly regulates response times for many government-backed plans. Here’s how:
- Under CMS-0057-F, insurance payers, including Medicaid and Medicare Advantage, must provide a prior authorization decision within 7 calendar days.
- The pre-authorization turnaround time is mandated at 72 hours for urgent medical needs.
- If a PA request is denied, payers must provide a specific reason for the denial to assist with the appeals process.
Shift to Electronic Prior Authorization (ePA) and APIs
The 2026 CMS Interoperability Standards and Prior Authorization for Drugs guidelines transition from traditional fax-based submissions toward standardized electronic systems.
Here’s how:
- Insurance payers are required to implement Fast Healthcare Interoperability Resources (FHIR) based Application Programming Interfaces (APIs). This means the dermatology practices’ EHR software can now interact directly with the payer’s system to check the prior authorization documentation requirements.
- Moreover, the real-time data exchange system is designed to reduce staff time spent on PA-related tasks.
Specialized Documentation For Biologics
As high-cost biologics and new small-molecule inhibitors enter the market in 2026, documentation requirements have become more quantitative. For example, Difamilast for atopic dermatitis and Lcotrokinra for psoriasis.
Here’s how:
- Prior authorization approvals require you to document specific clinical scores, such as Body Surface Area (BSA) percentage or Psoriasis Area and Severity Index (PASI). This data, when included in the medical records, helps you justify the medical necessity of the biologics.
- Besides, many insurance plans require a trial and failure of specific preferred agents before approving second-line biologic therapies.
Dermatology Procedures with Complex Authorization Processes
Some of the major dermatology procedures that require prior authorization are discussed below:
Phototherapy and Laser Treatments
Do you want to perform UVB or Excimer lasers for psoriasis or vitiligo for your patients? If so, be aware that insurance carriers frequently scrutinize these care services.
What makes obtaining the PA challenging is that payers require you to document the percentage of BSA affected. That’s not all, your documentation must also establish that the condition is functionally impairing rather than just a cosmetic concern.
Biologic Injections
Even though the injection code, such as CPT code 96372, is simple, the buy-and-bill model for the drugs, such as Cosentyx and Stelara, requires the dermatologist to acquire prior authorization.
Additionally, the documentation requirements for prescribing these drugs are extensive. Besides, payers may demand the proof of step therapy, i.e., failure of conservative treatments, before approval.
Destruction of Benign or Premalignant Lesions
Are you getting frequent denials on your medical claims against CPT codes 17000 or 17110? That is because the payer generally considers these procedural codes cosmetic unless the dermatologist can justify that the lesions are symptomatic.
For example, the patient’s medical records document symptoms such as itching, bleeding, or signs of malignancy.
Mohs Micrographic Surgery
The surgical procedures covered under CPT codes 17311 and 17313 are specialized, multi-stage procedures for skin cancer.
Therefore, insurance carriers require pathology reports and specific site maps before you can render these services. The reason? These details help justify the complexity and the number of stages you will perform.
Patch Testing for Allergies
When it comes to patch testing, such as CPT code 95044, prior authorization hinges on the number of allergens the dermatologist wants to test.
But why so? Because many insurance carriers have strict limits on the quantity of patches. Besides, the patient’s medical records must document a detailed history of contact dermatitis that standard topical steroids were unable to treat.
Key Factors Behind Prior Authorization Denials in Dermatology
Listed below are some of the key factors behind prior authorization denials in dermatology:
- Many payers label treatments for conditions like hair loss, acne, or scar revision as cosmetic. Thus, these result in pre-authorization denial despite their clinical impact.
- What happens when the documentation does not support that the patient failed lower-cost topical or oral treatments before moving to expensive biologics? It results in prior authorization denial.
- Prescribing a brand-name biologic or topical when a preferred, lower-cost alternative exists on the payer’s formulary is another common cause of pre-authorization denial.
- You may receive a pre-authorization denial when the clinical documentation does not contain severity scores, such as PASI or BSA, or the required photographic evidence.
- If you fail to provide detailed records of previous treatments or specialist consultations justifying the current care plan, gear up for a prior authorization denial.
- Simple mistakes such as incorrect patient IDs, expired insurance, or submitting the request to the wrong payer department can also result in a pre-authorization denial.
Streamline Prior Authorization With NeuraBill
With that said, it is time to conclude. To summarize, prior authorization challenges in dermatology practices pose a high risk, impacting the overall profitability. Hopefully, with this comprehensive guide as your go-to resource, you can easily overcome the pre-authorization intricacies.
However, if you still struggle, feel free to outsource dermatology billing services to professionals, like NeuraBill. With specialty-specific HIPAA-compliant services, around-the-clock support, and a dedicated account manager, we can fast-track pre-approvals for dermatology procedures and help you uptick your revenue by up to 15%.
